All Stories

  1. Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population

    Article • Leukemia & Lymphoma, September 2019, Taylor & Francis

    Dr Tomas Jelinek

  2. PD-1/PD-L1 inhibitors in haematological malignancies: update 2017

    Article • Immunology, August 2017, Wiley

    Dr Tomas Jelinek

  3. Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity

    Article • Hematological Oncology, September 2016, Wiley

    Dr Tomas Jelinek

  4. Monoclonal antibodies — A new era in the treatment of multiple myeloma

    Article • Blood Reviews, March 2016, Elsevier

    Dr Tomas Jelinek

  5. Plasma cell leukemia: from biology to treatment

    Article • European Journal Of Haematology, March 2015, Wiley

    Dr Tomas Jelinek